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Objective: Alterations of the gut microbiome in Parkinson disease (PD) have been repeatedly demonstrated. However,
little is known about whether such alterations precede disease onset and how they relate to risk and prodromal
markers of PD. We investigated associations of these features with gut microbiome composition.
Methods: Established risk and prodromal markers of PD as well as factors related to diet/lifestyle, bowel function, and
medication were studied in relation to bacterial α-/β-diversity, enterotypes, and differential abundance in stool samples
of 666 elderly TREND (Tübingen Evaluation of Risk Factors for Early Detection of Neurodegeneration) study
participants.
Results: Among risk and prodromal markers, physical activity, occupational solvent exposure, and constipation showed
associations with α-diversity. Physical activity, sex, constipation, possible rapid eye movement sleep behavior disorder
(RBD), and smoking were associated with β-diversity. Subthreshold parkinsonism and physical activity showed an inter-
action effect. Among other factors, age and urate-lowering medication were associated with α- and β-diversity. Physical
inactivity and constipation were highest in individuals with the Firmicutes-enriched enterotype. Constipation was lowest
and subthreshold parkinsonism least frequent in individuals with the Prevotella-enriched enterotype. Differentially
abundant taxa were linked to constipation, physical activity, possible RBD, smoking, and subthreshold parkinsonism.
Substantia nigra hyperechogenicity, olfactory loss, depression, orthostatic hypotension, urinary/erectile dysfunction, PD
family history, and the prodromal PD probability showed no significant microbiome associations.
Interpretation: Several risk and prodromal markers of PD are associated with gut microbiome composition. However,
the impact of the gut microbiome on PD risk and potential microbiome-dependent subtypes in the prodrome of PD
need further investigation based on prospective clinical and (multi)omics data in incident PD cases.
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The presence of gastrointestinal pathological α-syn-uclein deposits and constipation in prodromal and
clinically established Parkinson disease (PD) suggests an
integral role of the gut–brain axis for the early pathogene-
sis of PD.1–3 The synucleinopathy is hypothesized to
ascend via the vagal nerve from peripheral neurons of the
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gastrointestinal tract to the brain.4 Moreover, increased
intestinal permeability,5 elevated stool inflammatory cyto-
kines,6 and colonic wall inflammation7 have been shown
in PD patients, and may also represent key gastrointestinal
processes in prodromal PD. Mice overexpressing α-syn-
uclein show aggravated motor dysfunction when colonized
with intestinal microbiota from PD patients.8 However,
the specific role of gut microbiota for PD and the factors
modulating such processes along the microbiota–gut–
brain axis are still largely unknown. The most consistently
shown PD-related changes of gut microbial composition
include an increase in the relative abundances of Ver-
rucomicrobiaceae and Akkermansia and a decrease in
Prevotellaceae and Prevotella.9,10 The latter has also been
associated with progressive PD motor symptoms over
2 years11 and with rapid eye movement sleep behavior dis-
order (RBD),12 a highly specific prodromal marker of PD.
Prospective evidence of several PD risk markers (indicating
an increased PD risk) and prodromal markers (indicating
an already initiated neurodegenerative process) confirm
the concept of a prodromal phase preceding clinically
established PD by years or even decades.13 Based on this
evidence, it is possible to define specific predictive values
for these markers and to calculate individual prodromal
PD probabilities based on age and marker profiles.14,15
Age16 and several markers established in the International
Parkinson and Movement Disorder Society (MDS)
research criteria for prodromal PD14,15 have also been
associated with gut microbial changes; these include risk
markers such as male sex,17 diabetes,18 nonsmoking, and
nonuse of caffeine16,17 and prodromal markers, such as
RBD,12 constipation,16 and depression.19 Moreover, phys-
ical inactivity, a risk marker for PD15 and for most major
chronic diseases occurring frequently in old age,20 has
been reported to affect microbial β-diversity in elderly
males21 as well as various inflammatory and immune pro-
cesses.22 However, these studies focused on microbial
associations with single or few PD-related markers, or
studied very small samples considering the multitude of
other markers and confounding factors that may modulate
the gut microbiome. For instance, factors related to diet,
bowel function, and disease/medication often exert effects
on microbial composition,16–18 and may thus bias findings
of marker associations. The present study therefore
assessed gut microbial diversity, enterotypes, and taxo-
nomic composition and investigated their associations
with a comprehensive set of PD risk and prodromal
markers, the overall prodromal PD probability, and a wide
range of other potential confounders in a large sample of
elderly individuals.
Patients and Methods
All subjects were participants of the prospective Tübingen
Evaluation of Risk Factors for Early Detection of Neu-
rodegeneration (TREND) study. The cohort has been
enriched regarding an increased PD risk by partly rec-
ruiting participants based on the presence of olfactory loss,
depression, and/or possible RBD. Biennial comprehensive
assessments in 1,202 individuals have been performed
over the past 10 years (www.trend-studie.de/english).
Stool samples were collected at the third follow-up of the
study and associated with markers/factors assessed at the
corresponding wave of assessments. Stool was sampled
using collection tubes containing a DNA stabilizer (PSP
Spin Stool DNA Plus Kit; STRATEC Molecular,
Birkenfeld, Germany), provided using postal services and
frozen and stored at −80C immediately upon arrival.
Samples were available from 745 participants. After
excluding individuals taking antibiotic medication
(n = 47), patients with PD (n = 11) or atypical/secondary
parkinsonism (n = 2), incident cases of PD (n = 3), and
individuals with missing dietary and medication data
(n = 16), data from 666 individuals were included in the
analyses.
In total, 9 risk and 9 prodromal markers as defined
by the recently updated MDS research criteria for pro-
dromal PD were selected a priori and investigated for
associations with microbial measures.15 We assessed the
PD risk markers male sex, substantia nigra hyper-
echogenicity (transcranial ultrasound), nonsmoking, no
consumption of coffee (cups per day), positive PD family
history (first-degree relatives), physical activity (ie, low
activity levels as measured using hours of sport/wk), type
2 diabetes (diagnosis), and occupational solvent and pes-
ticide exposure (self-reported). Prodromal markers com-
prised olfactory loss (Sniffin’ Sticks, 16 SS), depression
(acute or lifetime diagnosis), constipation (Rome III
criteria, sum score),23 possible RBD (RBD screening
questionnaire), excessive daytime somnolence, erectile
and urinary dysfunction, and symptomatic orthostatic
hypotension (the latter 3 assessed using the Unified Mul-
tiple System Atrophy Rating Scale questionnaire as
described previously).24 Moreover, motor deficits indicat-
ing subthreshold parkinsonism were assessed using the
MDS Unified Parkinson’s Disease Rating Scale part III25
(score > 6 after excluding action/postural tremor items;
scores from 3 to 6 were defined as borderline motor defi-
cit).14 Furthermore, 90 additional variables were consid-
ered comprising:
• Eighty variables that were screened as potential con-
founders for adjustment in the statistical analyses (see
statistical approach below)
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• Seven generic/physiological variables (eg, age, body
mass index [BMI], education, and exhaustion from
climbing 3 levels of stairs [no, yes, not capable])
• Five variables related to bowel function (eg, irritable
bowel syndrome, bloating, vomiting/diarrhea)
• Sixteen diet-related variables (assessing weekly meat,
vegetables, dairy, protein, carbohydrate, and alcohol
consumption)
• One variable on gout
• Fifty-one variables related to medication
• Exploratory variables that measure further aspects of
prodromal PD or represent alternative (yet less
established)14 groupings/definitions of risk/prodromal
markers
• Prodromal PD probability values, and diagnoses of
possible (>50% probability) and probable prodromal
PD (>80%) as calculated based on age and compre-
hensive individual marker profiles according to the
MDS research criteria for prodromal PD14
• Exploratory alternative groupings/definitions of risk/
prodromal markers comprised 3 variables on (func-
tional) constipation, 2 variables on smoking status/
history, and 2 variables on motor ratings
For the complete list of the 18 risk and prodromal
markers and the 90 additional variables, their specific
assessment methods, variable definitions, and descriptive
statistics, see the Supporting Material. The study was
approved by the local ethical committee (Medical Faculty,
University of Tübingen; 444/2019BO2). All participants
provided written informed consent.
Stool Sample DNA Extraction, Library
Preparation, and Sequencing
DNA extraction, library preparation, and sequencing were
performed at the DNA Sequencing and Genomics Labora-
tory of the Institute of Biotechnology, University of Hel-
sinki. All samples were stored at −80C and randomized
in a −20C room before bulk DNA extraction with the
PSP Spin Stool DNA Plus Kit (STRATEC Molecular).
One blank was added per extraction batch to assess poten-
tial contamination. After extraction, DNA concentrations
were measured with NanoDrop ND-1000 (Thermo
Fisher Scientific, Waltham, MA). V3–V4 regions of the
bacterial 16S ribosomal RNA gene were amplified in Ver-
ity 96-well Thermal Cyclers (Thermo Fisher Scientific)
using a previously described polymerase chain reaction
(PCR) protocol.11 The amount of template DNA used for
the first PCR ranged between 11.25 ng and 1311.26 ng.
Each PCR batch included blank samples for assessment of
potential contamination. Dual indexes were used in the
second PCR; these had been selected using BARCOSEL26
to allow pooling and sequencing of all samples in 1 pool
run on 3 separate runs on a MiSeq (Illumina, San Diego,
CA; v3 600 cycle kit, forward/reverse read length 328/278
bases). Thus, each sample was sequenced 3 times among
all the other samples, reducing possible batch effects.
Sequence Analysis
The raw sequence data contained 48,782,168 sequence
reads (availability: ENA accession number PRJEB32920).
We combined the sequence reads from the 3 sequencing
runs, and then trimmed primers and low-quality
sequences with cutadapt (v1.8.3,27 parameters q = 30 and
m = 160). Merging paired reads, alignment to a reference
database (SILVA, v132), chimera removal, taxonomic clas-
sification (reference database: Ribosomal Database Project
(RDP), v16, 16S rRNA reference (PDS)), and operational
taxonomic unit (OTU) clustering (“cluster.split”
approach) were run with mothur (v1.40.0),28 following
the standard operating procedure (SOP) for MiSeq data.29
Parameters differing from the SOP were maxlength = 500
and maxhomop = 8 for the first “screen.seqs,” start = 2
and end = 17012 for the second “screen.seqs,” diffs = 4
for “pre.cluster,” cutoff = 70 for “classify.seqs,” and keep-
ing archaeal sequences in “remove.lineage.” Additionally,
singleton sequences were removed prior to “classify.seqs”
using “split.abund” with cutoff = 1. After excluding data
from blanks and all OTUs with ≤10 sequence reads, the
final dataset consisted of 25,390,744 sequence reads
(34,082 ± 4,785 per sample).
Microbial Measures
All microbiota analyses were performed using genus-level
data. α-Diversity was estimated with the inverse Simpson
index (R package: phyloseq).30 This index summarizes rich-
ness (number of different taxonomic units) and evenness
(abundance distribution of taxonomic units) for each sam-
ple. The measure chosen for β-diversity was Bray–Curtis
dissimilarity (R package: vegan). It quantifies the intersample
compositional dissimilarity based on both presence/absence
of taxonomic units and their abundances. Nonmetric multi-
dimensional scaling (NMDS; R package: vegan) was applied
to produce an ordination based on rank orders in the Bray–
Curtis dissimilarity matrix, and to plot compositional dis-
similarities between samples (and groups of samples) in a 2-
dimensional ordination space.
Microbial enterotypes31 were determined using the
algorithm provided at http://enterotypes.org/. All unclassi-
fied taxa (genus level) were excluded from α-diversity,
enterotype, and differential abundance analyses. For differ-
ential abundance, analyses were also performed for the
family level and OTU level.
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Statistical Analyses
The present study investigates possible associations of 18
single risk and prodromal markers with different microbial
measures. To investigate this primary objective, potentially
confounding effects of 80 different factors were considered
for adjustment of risk and prodromal marker effects in the
statistical analysis. Moreover, 10 variables measuring addi-
tional aspects of PD (eg, prodromal PD probabilities) or
alternative marker groupings/definitions entered the ana-
lyses as exploratory variables (mentioned above and listed
in the Supporting Material). The study used a 2-stage sta-
tistical analysis approach. First, in a prescreening step,
each of the 18 risk and prodromal markers as well as each
of the 90 additional variables were tested separately (for
specific tests, see below) for associations with microbial
measures (α-diversity, β-diversity, enterotypes). Here,
markers/variables showing effects with p < 0.1 were
selected for subsequent multifactorial statistical modeling.
From the multiple measures of constipation, smoking,
and motor function, the variable with the lowest p value
was selected. Results of the prescreening step are shown in
the Supporting Material. In a second step, all selected risk
and prodromal markers and additional confounding
adjustment factors were entered into multifactorial statisti-
cal models, and model selection was performed with final
models only comprising markers/factors showing marginal
effects with p < 0.1 (bolded p values in the Supporting
Material: single variable association). Because the primary
objective of the study was association testing for the 18
risk and prodromal markers (which were tested at least in
the prescreening step), Bonferroni corrections for n = 18
tests were applied in the multifactorial tests, and effects of
the 18 markers with a corrected threshold of p < 0.003
were considered significant. For adjustment factors, no
correction for multiple testing was applied (p < 0.05). In
enterotype analyses, differences between all 3 enterotype
groups were statistically tested post hoc pairwise, and
accordingly effects with p < 0.0009 were considered
significant after correction for multiple testing for
n = 18 × 3 = 54 tests.
Linear multiple regressions of α-diversity were per-
formed. Associations of markers/factors with β-diversity
were tested using PERMANOVAs (single variable: adonis,
multifactorial: adonis2, both commands from the R pack-
age vegan). Moreover, α- and β-diversity were tested for
interaction effects between physical activity and other risk
and prodromal markers of PD. Marker/factor differences
between enterotypes were tested using Fisher exact tests
and Kruskal–Wallis tests, and subsequent multifactorial
analyses using multinomial logistic regressions with
enterotype as dependent variable.
For differential abundance analysis, we used
DESeq2, a method based on generalized linear models
with negative binomial distributions (sequence count
data). The DESeq2 model included all covariates
accounted for in the final PERMANOVA model for
β-diversity, and p values were adjusted for multiple testing
using false discovery rate (FDR) corrections accounting
for the number of different taxa tested. We used R
(v3.5.1) for all analyses and figures. TREND study data
were collected and managed using REDCap electronic
data capture tools hosted at the University of Tübingen.
Results
Descriptive Statistics
The TREND study sample (n = 666) had a mean age
(±SD, range) of 68.4 ± 6.3 years (53–86). Risk and prodro-
mal marker variables showed the following descriptive statis-
tics: male sex (52.7%), substantia nigra hyperechogenicity
(21.6%), positive PD family history (14.7%), physical inac-
tivity (no activity, 25.7%; <1 h/wk, 30.9%; 1–2 h/wk,
24.2%; 2–4 h/wk, 8.3%; >4 h/wk, 10.4%), nonsmoking
(never, 6.8%; former, 46.7%; current smoker, 46.5%),
nonuse of coffee (14.4%), type 2 diabetes (8.3%), occupa-
tional solvent exposure (10.8%), occupational pesticide
exposure (1.3%), olfactory loss (19.7%), depression
(31.5%), constipation (severity sum score = 3.1 ± 3.9,
range = 0–25), possible RBD (12.6%), excessive daytime
somnolence (3.8%), erectile dysfunction (in males, 21.5%),
urinary dysfunction (5.1%), symptomatic orthostatic hypo-
tension (4.7%), and regarding motor functions, no motor
deficit (90.5%), borderline motor deficit (6.0%), and sub-
threshold parkinsonism (3.5%). Based on prodromal PD
probabilities (3.8 ± 11.4%, 0.0–89.1%), 15 individuals
(2.3%) were diagnosed with possible prodromal PD and 5
individuals (0.8%) with probable prodromal PD. The most
abundant bacterial genus in the subjects’ stool samples was
Bacteroides, followed by Faecalibacterium, Gemmiger,
Roseburia, Prevotella, and Ruminococcus (Fig 1).
FIGURE 1: Relative abundances of the 10 most common
bacterial genera.
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α-Diversity
α-Diversity on the genus level as indicated by the inverse
Simpson index showed associations (p < 0.05) with 2 risk
markers, 1 prodromal marker, and 4 additional adjust-
ment factors (Table 1). Overall, the multiple regression
model explained 8.0% of α-diversity variance (adjusted
R2). Constipation severity and age were positively associ-
ated with α-diversity, whereas physical activity and occu-
pational solvent exposure as well as intake of thyroid
medication, urate-lowering medication, and exhaustion
from walking stairs were inversely associated with α-diver-
sity (Fig 2). None of the selected variables showed an
interaction (p > 0.1) with physical activity on α-diversity.
When entering motor deficits into the regression, no asso-
ciation with α-diversity was observed (p > 0.1), and the
interaction of motor deficits and physical activity was non-
significant (p = 0.088).
β-Diversity
Intersample differences in microbial composition as indi-
cated by β-diversity showed significant associations with
multiple risk and prodromal markers of PD (Table 2). In
addition to age, physical activity, constipation, and BMI
explained most of the variance (R2; Fig 3). Moreover, sex,
smoking, possible RBD, different medications, and dark
bread consumption showed associations with β-diversity.
Although motor deficits showed no effect, the interaction
between physical activity and motor deficits explained var-
iance in β-diversity (p = 0.002).
Enterotypes
Bacteroides-enriched (70.9% of samples) microbiomes
were more frequent compared to Prevotella-enriched
(21.5%) and Firmicutes-enriched (7.7%) microbiomes.
Enterotypes differed in several risk and prodromal markers
and additional factors (Table 3). For instance, the lowest
physical activity levels as well as most severe constipation
were observed for the Firmicutes-enriched enterotype
(Fig 4). Higher physical activity levels were linked to the
Bacteroides-enriched enterotype. Constipation severity was
lowest and subthreshold parkinsonism least frequently
observed in individuals with the Prevotella-enriched
enterotype.
TABLE 1. Association of α-Diversity with Risk and Prodromal Markers of Parkinson Disease and Additional
Factors
Estimate SE p
Intercept 4.05 1.24 0.00113a
Risk markers
Physical activity (h sport/wk) −0.23 0.09 0.00765b
Occupational solvent exposure (no, yes) −0.91 0.32 0.00401b
Prodromal markers
Constipation (number of fulfilled Rome III criteria
items of functional constipation)
0.23 0.12 0.04540b
Subthreshold parkinsonism (no, borderline, yes) 1.06 0.56 0.05930
Physical activity × subthreshold parkinsonism −0.33 0.19 0.08769
Additional adjustment factors
Age (yr) 0.03 0.02 0.04757b
Exhaustion from climbing stairs (no, yes, not capable) −0.75 0.21 0.00038b
Urate-lowering medication (no, yes) −1.25 0.47 0.00812b
Thyroid medication (no, yes) −0.61 0.24 0.00951b
Total dairy consumption (score) −0.20 0.11 0.07369
aSignificant effects of risk and prodromal markers in multiple regression models after Bonferroni correction for multiple testing (p < 0.003).
bEffects with an uncorrected p < 0.05.
SE = standard error.
324 Volume 88, No. 2
ANNALS of Neurology
FIGURE 2: α-Diversity and physical motor measures. Magnitude of α-diversity by (A) levels of weekly physical activity, (B) physical
exhaustion, and (C) physical activity levels in different motor deficit groups.
TABLE 2. Associations of β-Diversity with Risk and Prodromal Markers in Parkinson Disease and Additional
Factors
R2 F p
Risk markers
Physical activity (h sport/wk) 0.014 9.09 0.001a
Male sex (no, yes) 0.006 3.59 0.003a
Smoking (pack-years) 0.004 2.36 0.020b
Prodromal markers
Constipation (sum score of Rome III criteria
items of functional constipation)
0.009 5.48 0.002a
Possible RBD (no/yes) 0.003 2.14 0.037b
Subthreshold parkinsonism (no, borderline, yes) 0.002 1.45 0.159
Physical activity × subthreshold parkinsonism 0.006 3.56 0.002a
Additional adjustment factors
Age (yr) 0.008 4.88 0.001b
Diabetes medication (no, yes) 0.004 2.66 0.011b
Urate-lowering medication (no, yes) 0.004 2.43 0.016b
Beta-blocker medication (no, yes) 0.003 1.91 0.060
Dark bread (no, yes) 0.003 2.19 0.034b
BMI (kg/m2) 0.013 8.41 0.001b
aSignificant effects of risk and prodromal markers in permutational multivariate analysis of variance models after Bonferroni correction for multiple
testing (p < 0.003).
bEffects with an uncorrected p < 0.05.
BMI = body mass index; RBD = rapid eye movement sleep behavior disorder.
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Differential Abundance
Several of the variables associated with β-diversity were
also linked to the abundances of specific taxa (Supporting
Material; all p values FDR-corrected). The variable with
the most differentially abundant taxa was constipation
(Table 4). Of taxa previously associated with PD on the
genus level,10 increased constipation severity was signifi-
cantly associated with decreased abundance of
Faecalibacterium (p = 0.022) and Roseburia (p = 0.008),
physical exhaustion with a decrease in Bifidobacterium
(p = 0.039), and possible RBD with a decrease in Lactoba-
cillus (p = 0.023). Further, motor deficits indicating sub-
threshold parkinsonism were associated with a decrease in
Odoribacter (p = 0.031). Possible RBD was further associ-
ated with a decrease in Faecalicoccus (p = 0.017) and
Victivallis (p = 0.017), and an increase in the abundance
of Haemophilus (p = 0.003). Urate-lowering medication
was associated with higher abundance of Clostridium III
(p = 0.005) and Parasutterella (p = 0.032). The taxa
Prevotella and Akkermansia were not statistically significant
in any of the differential abundance comparisons.
Discussion
The present study investigated associations between gut
microbial composition, risk markers and prodromal
markers of PD, subthreshold parkinsonism, and a wide
range of potential confounders in 666 elderly individuals.
Among these markers, particularly physical activity, consti-
pation, possible RBD, smoking, and subthreshold parkin-
sonism were associated with alterations in microbial
community composition. Moreover, age, sex, occupational
solvent exposure, and an interaction of subthreshold par-
kinsonism and physical activity were associated with dif-
ferent microbial measures. As expected, effect sizes of
individual markers and factors (≤1% explained variance)
and multifactorial models (8%) were small.16,17 None of
the microbial measures was associated with substantia
nigra hyperechogenicity, olfactory loss, depression, ortho-
static hypotension, urinary/erectile dysfunction, family his-
tory of PD, or the overall prodromal PD probability
calculated based on marker profiles of individuals.
The relative abundances of bacterial taxa were
mostly similar to other samples of healthy elderly individ-
uals.32 Lower relative abundance of, for example, Bacte-
roides compared to previous findings may be explained by
differences in cohort composition due to recruitment,
demographic, regional, and/or lifestyle factors.
Age, constipation, and low physical activity were
associated with increasing and occupational solvent expo-
sure with decreasing within-sample α-diversity. Higher
α-diversity in PD patients compared to controls has been
reported,33–35 yet overall evidence is inconsistent,10 and it
is unclear whether α-diversity and PD are linked. Similar
to our results, older age in an elderly population has been
associated with higher α-diversity.36 However, statistical
modeling of such effects is complicated by the diseases,
medications, and lifestyle changes often associated with
advanced age. Regarding constipation, higher α-diversity
has been linked to harder stool consistency16 and func-
tional constipation.37 Autonomous dysfunction related to
prodromal PD may contribute to these α-diversity effects,
which however need to be disentangled from other poten-
tially important factors, such as diet, stool water content
and transit time, and bacterial growth rates.38 Physical
inactivity increases the risk of many chronic diseases20
including PD15; conversely, being active may lead to lower
prevalence of prodromal PD markers such as
FIGURE 3: Nonmetric multidimensional scaling (NMDS) plots
in 2-dimensional space (MDS1 and 2) of factors showing
significant Bray–Curtis distance differences. Differences in
microbial composition between (A) age groups, (B) groups
with different physical activity levels, and (C) groups
stratified by severity of constipation are shown. Circles
indicate 95% confidence intervals.
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constipation.39 The effects of inactivity could be related to
the processes observed in PD, that is, increased colonic
inflammation,7 immune responses,6 and intestinal barrier
permeability.5 Exhaustion from climbing stairs, an indica-
tor of low cardiorespiratory fitness, was associated with a
reduction in α-diversity, in line with earlier studies indi-
cating lower diversity in lower fitness40 and frailty.41 This
apparently contradictory result may be partly explained by
differences between physical activity and capability. More-
over, the PD risk marker occupational solvent exposure15
was associated with a decrease in α-diversity. Strengths
and directions of effects of different risk and prodromal
markers on microbial composition may vary based on the
underlying pathophysiological pathways, potentially
explaining why the overall prodromal PD probability cal-
culated based on comprehensive marker profiles showed
no significant association with α-diversity.
β-Diversity (between samples) has been consistently
shown to differ between PD patients and controls.10 Sev-
eral PD risk and prodromal markers were associated with
β-diversity even in multifactorial models while considering
potential confounders. These findings suggest that micro-
bial composition might already be altered in the
prodromal phase of PD. Although α- and β-diversity are
not directly related, constipation and physical inactivity
were again among the variables explaining most of the var-
iance. While showing a nonsignificant interaction effect
for α-diversity (p = .088), physical activity and motor defi-
cits indicating subthreshold parkinsonism showed a signif-
icant interaction effect for β-diversity, and thus between-
sample dissimilarities in microbial composition depend on
the interaction of both markers. It remains speculative to
what degree these associations play a specific role in pro-
dromal PD. Links between β-diversity and possible RBD,
sex, and smoking further support the concept of microbial
changes preceding PD. While replicating effects of anti-
diabetic and beta-blocker medication,17 our study showed
the most consistent associations of α- and β-diversity and
differential abundance for urate-lowering medication.
Urate is a powerful antioxidant linked to reduced PD
risk,14 and our results may implicate gut microbiota in
this context. Dark bread was the only dietary factor associ-
ated with β-diversity. Dark bread can be seen as an indica-
tor of high fiber consumption, and thus presumably better
intestinal barrier integrity and short-chain fatty acid
(SCFA) production.42 Because both have been suggested
TABLE 3. Associations of Enterotypes with Risk and Prodromal Markers of Parkinson Disease and Additional
Factors
Bacteroides vs
Firmicutes
Bacteroides vs
Prevotella
Firmicutes vs
Prevotella
Estimate SE p Estimate SE p Estimate SE p
Intercept −1.44 0.44 0.00092a −0.28 0.26 0.28121 1.17 0.47 0.01299b
Risk markers
Physical activity (h sport/wk) −0.58 0.16 0.00031a −0.25 0.09 0.00313b 0.33 0.17 0.05763
Male sex (no, yes) −0.60 0.34 0.08162 0.25 0.20 0.22016 0.85 0.38 0.02355b
Prodromal markers
Constipation (sum score of Rome III
criteria items of functional constipation)
0.07 0.03 0.02404b −0.07 0.03 0.04502b −0.14 0.04 0.00133b
Subthreshold parkinsonism
(no, borderline, yes)
0.43 0.30 0.14722 −0.36 0.30 0.23427 −0.79 0.40 0.04628b
Additional adjustment factors
Legumes (score) −1.08 0.36 0.00285b 0.07 0.18 0.67751 1.16 0.39 0.00274b
Functional bloating (no, yes) 0.95 0.45 0.03235b −0.59 0.46 0.20614 −1.54 0.59 0.00906b
Vegetarian (no, yes) 1.05 0.51 0.04091b 0.38 0.57 0.50650 −0.68 0.65 0.29823
aSignificant effects of risk and prodromal markers in logistic regressions after Bonferroni correction for multiple testing (also considering 3 group com-
parisons, p < 0.0009).
bEffects with an uncorrected p < 0.05.
SE = standard error.
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to be impaired in PD5,43 and to play a role in several pro-
cesses along the microbiota–gut–brain axis,42 dietary fac-
tors might also be important in prodromal PD. After
physical activity, BMI explained the most variance in
β-diversity. For some dietary factors linked to BMI, inde-
pendent effects might have been too small to reach the
threshold for statistical significance.
Subthreshold parkinsonism was least frequently pre-
sent in individuals with the Prevotella-enriched compared
to the Firmicutes-enriched enterotype. This finding is in
line with the reduced abundance of Prevotella in PD,10 in
more severely progressing PD,11 and in RBD12 compared
to controls. Thus, the present study supports the relevance
of Prevotella in prodromal PD. Microbial changes due to
constipation are often argued to confound microbiome
analysis of PD patients. The Prevotella-enriched enterotype
was also the least common in individuals with high consti-
pation severity scores. Subjects with high scores typically
had the Firmicutes-enriched enterotype in accordance with
previous findings.44 Viewing constipation in PD as being
linked to a disturbed enteric nervous system showing simi-
lar cellular changes to those of affected brain structures
may suggest common relevance of Prevotella for prodromal
dysautonomic and motor deficits. In this light, constipa-
tion may not be confounding, but may reflect a common
pathogenic process. Although constipation may exert
effects on microbial composition via several plausible
mechanisms, such effects may be different in diseased
individuals as compared to healthy subjects, as recently
demonstrated in PD for the association between α-diver-
sity and stool consistency.11 Physical inactivity was more
frequently observed in individuals with the Firmicutes-
enriched enterotype, whereas the Bacteroides-enriched
enterotype was more frequent in active subjects. Although
consistent with some evidence gained from human45 and
mouse studies,46 processes underlying the links between
physical activity, other prodromal markers in PD,39 obe-
sity, nutrition, and microbial composition are complex
and need to be further investigated.
The results of differential abundance analyses were
partly consistent with previous findings, but some taxa
reported for PD10 and RBD12 showed no association with
risk and prodromal markers. In contrast with enterotype
analyses, no significant differential abundance effect was
observed for Prevotella, which may be partly explained by
differences in covariates considered. Among other candi-
date genera, Akkermansia showed no significant association
with any of the risk and prodromal markers. However,
possible RBD showed several differentially abundant taxa,
which have not been previously associated with PD10 or
RBD12 (Faecalicoccus, Victivallis, and Haemophilus). Lacto-
bacillus was decreased in individuals with possible RBD,
whereas an increase in PD patients has previously been
shown repeatedly.10 It is possible that subtypes of prodro-
mal PD exist with varying involvement of the gut (eg,
RBD representing a subtype with early autonomic dener-
vation).47 Also, the microbiome may (differentially)
change over time, that is, from prodromal to clinically
established PD. Such complexity may hamper the identifi-
cation of (prodromal) PD-related microbiome signatures.
However, these signatures may allow for early stratification
of individuals based on their microbiome (and underlying
or inherent pathologies), and early and targeted therapeu-
tic interventions.
FIGURE 4: Enterotype group differences regarding (A)
proportions of levels of physical activity, (B) severity of
constipation, and (C) proportions of individuals with motor
deficits indicating subthreshold parkinsonism. *Significant
after Bonferroni correction (p < 0.0009); (*) indicates effects
with an uncorrected p < 0.05.
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Constipation severity was significantly associated
with decreased abundance of Faecalibacterium and Blautia,
SCFA-producing taxa that can exert positive effects on the
intestinal mucosa48 and are decreased in PD.10 The find-
ing of a decrease in Odoribacter in individuals with sub-
threshold parkinsonism has potential relevance for
prodromal PD. Odoribacter is a taxon involved in SCFA
production and tryptophan metabolism. It might be rele-
vant for gastrointestinal integrity and serotonergic bowel
dysfunction (prolonged transit time) as well as central ner-
vous dysfunction (anxiety) as suggested by findings in an
autism mouse model.49
The present study has several limitations. (1) Some
markers, and dietary and medication data, were assessed
using self-reports. Although those assessments were struc-
tured and highly standardized, quantitative measures or
medical records might be more accurate, for example, for
assessing physical activity, diets and medication. (2) Inter-
action analyses were limited to those involving physical
activity, given its relevance as a PD risk marker15 and for
prodromal PD markers.39 Further research on marker
interactions and clusters as well as factors underlying
potential biases is needed to better model the complexity
of microbial associations. (3) Stool samples were not fro-
zen immediately after defecation but after postal delivery,
and the delay may constitute a technical confounder.
However, collection tubes contained a DNA stabilizer,
and the impact of delayed freezing on microbial composi-
tion should therefore be minimal.11,50 (4) Some risk and
prodromal markers were present at lower frequency, and
lower statistical power might have contributed to some
non-significant findings.
In conclusion, several risk and prodromal markers in
PD, in particular markers related to motor aspects and
constipation, were associated with altered microbial α-
and β-diversity, enterotypes, and bacterial abundance.
Constipation, physical activity, possible RBD, urate levels,
smoking, and subthreshold parkinsonism might be partic-
ularly linked to the prodromal microbiome in PD. How-
ever, many other markers predictive of PD and overall
prodromal PD probability values showed no significant
association with any microbial measure. Prodromal micro-
bial changes might only be observable in subgroups with
specific marker constellations. The functional roles of
these markers and associated microbiota for intestinal per-
meability, stool immune mediators, colonic inflammation,
and the systemic interactions with the host organism need
further investigation. The prodromal microbiome(s) in
PD, temporal dynamics of microbiota toward PD diagno-
sis, and etiological relevance in prodromal PD should be
TABLE 4. Number of Differentially Abundant Taxa in Association with Risk and Prodromal Markers of Parkinson
Disease and Additional Factors in Multifactorial Models
Family Level Genus Level OTU Level
Risk markers
Physical activity (h sport/wk) 4 5 7
Smoking (pack-years) 1 1 12
Prodromal markers
Constipation (sum score of Rome III criteria
items of functional constipation)
10 25 51
Possible RBD (no, yes) 4 4 4
Subthreshold parkinsonism (no, borderline, yes) 0 1 4
Additional adjustment factors
Age (yr) 0 2 5
Exhaustion from climbing stairs (no, yes) 3 5 9
Urate-lowering medication (no, yes) 3 2 5
Antihypertensive medication (no, yes) 1 1 1
Diabetes medication (no, yes) 2 5 9
OTU = operational taxonomic unit; RBD = rapid eye movement sleep behavior disorder.
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investigated based on prospective marker profiles and
(multi)omics data in incident PD cases.
Acknowledgment
Samples were obtained from the Neuro-Biobank of the
University of Tübingen, Germany (https://www.hih-
tuebingen.de/en/about-us/core-facilities/biobank/). This
biobank is supported by the local university, the Hertie
Institute for Clinical Brain Research, and the German
Center for Neurodegenerative Diseases (DZNE). The
TREND study is being conducted at the University Hos-
pital Tübingen and has been supported by the Hertie
Institute for Clinical Brain Research, the DZNE, the
Geriatric Center of Tübingen, the Center for Integrative
Neuroscience, Teva Pharmaceutical Industries, Union
Chimique Belge, Janssen Pharmaceuticals, and the Inter-
national Parkinson Foundation. This study was funded
further by the Academy of Finland (295724, 310835) and
the Finnish Medical Foundation. The supporting institu-
tions had no influence on the design, conduct, or analysis
of the study.
We thank the participants for their continued partic-
ipation in the TREND study and for providing their stool
samples; the numerous (doctoral) students and study
nurses, who actively contributed to study organization,
and data collection, entry, and monitoring; Dr A. Caliebe
for statistical consultancy advice; and A. Gashi, E. Mus-
tanoja, and P. Collin for their work on biological sample
processing at the DNA Sequencing Lab.
Author Contributions
S.H.e., K.B., G.W.E., W.M., D.B., P.A., and F.S. con-
tributed to the conception and design of the study; S.H.
e., S.H.a., V.T.E.A., L.P., C.D., C.S., K.B., U.S., A.-K.v.
T., L.P., P.A., and F.S. contributed to the acquisition and
analysis of data; S.H.e., V.T.E.A., W.M., P.A., and F.S.
contributed to drafting the text and preparing the figures.
The TREND organization team consists of Corina
Maetzler, Susanne Nußbaum, Dr Anna-Katharina von
Thaler, Ulrike Sunkel, Christian Mychajliw, and Ramona
Täglich.
Data Availability
TREND data are available upon request. Microbiome
sequence raw data are available under the European
Nucleotide Archive accession number PRJEB32920.
Potential Conflicts of Interest
V.T.E.A., L.P., P.A., and F.S. are inventors on granted
patents related to the use of microbiota analysis in the
diagnosis of PD (FI127671B, US10139408B2) and pend-
ing patents related to the use of microbiota in the diagno-
sis and treatment of PD (US16/186,663, EP3149205).
These patents/patent applications are currently assigned to
NeuroInnovation Oy and licensed to NeuroBiome.
NeuroInnovation Oy provides clinical neurological ser-
vices for patients and health care providers as well as con-
sultant services in the field of neurology and microbiota.
NeuroBiome pursues the development and commercializa-
tion of diagnostic and therapeutic applications of micro-
biota for PD. Currently, no such products are marketed
by NeuroBiome or NeuroInnovation Oy. F.S. owns 85%
of shares of NeuroInnovation Oy and 100% of shares of
NeuroBiome. None of the abovementioned inventors has
received any fees or royalties from these companies related
to microbiota-related products, but they may do so in the
future if development and commercialization are success-
ful. F.S. is a member of the scientific advisory board of
and has received fees and stock options from Axial
Biotherapeutics, a company that is developing gut–brain
axis–related therapeutics for PD and autism spectrum
disorder.
References
1. Stokholm MG, Danielsen EH, Hamilton-Dutoit SJ, Borghammer P.
Pathological α-synuclein in gastrointestinal tissues from prodromal
Parkinson disease patients. Ann Neurol 2016;79:940–949.
2. Schrag A, Horsfall L, Walters K, et al. Prediagnostic presentations of
Parkinson’s disease in primary care: a case-control study. Lancet
Neurol 2015;14:57–64.
3. Abbott RD, Petrovitch H, White LR, et al. Frequency of bowel move-
ments and the future risk of Parkinson’s disease. Neurology 2001;57:
456–462.
4. Breen DP, Halliday GM, Lang AE. Gut–brain axis and the spread of
α-synuclein pathology: vagal highway or dead end? Mov Disord
2019;34:307–316.
5. Forsyth CB, Shannon KM, Kordower JH, et al. Increased intestinal
permeability correlates with sigmoid mucosa alpha-synuclein staining
and endotoxin exposure markers in early Parkinson’s disease. PLoS
One 2011;6:e28032.
6. Houser MC, Chang J, Factor SA, et al. Stool immune profiles evince
gastrointestinal inflammation in Parkinson’s disease. Mov Disord
2018;33:793–804.
7. Devos D, Lebouvier T, Lardeux B, et al. Colonic inflammation in
Parkinson’s disease. Neurobiol Dis 2013;50:42–48.
8. Sampson TR, Debelius JW, Thron T, et al. Gut microbiota regulate
motor deficits and Neuroinflammation in a model of Parkinson’s dis-
ease. Cell 2016;167:1469–1480. e12.
9. Scheperjans F, Aho V, Pereira PAB, et al. Gut microbiota are related
to Parkinson’s disease and clinical phenotype. Mov Disord 2015;30:
350–358.
10. Boertien JM, Pereira PAB, Aho VTE, Scheperjans F. Increasing com-
parability and utility of gut microbiome studies in Parkinson’s dis-
ease: a systematic review. J Parkinsons Dis 2019;9:S297–S312.
330 Volume 88, No. 2
ANNALS of Neurology
11. Aho VTE, Pereira PAB, Voutilainen S, et al. Gut microbiota in
Parkinson’s disease: temporal stability and relations to disease pro-
gression. EBioMedicine 2019;44:691–707.
12. Heintz-Buschart A, Pandey U, Wicke T, et al. The nasal and gut
microbiome in Parkinson’s disease and idiopathic rapid eye move-
ment sleep behavior disorder. Mov Disord 2018;33:88–98.
13. Mahlknecht P, Seppi K, Poewe W. The concept of prodromal
Parkinson’s disease. J Parkinsons Dis 2015;5:681–697.
14. Berg D, Postuma RB, Adler CH, et al. MDS research criteria for pro-
dromal Parkinson’s disease. Mov Disord 2015;30:1600–1611.
15. Heinzel S, Berg D, Gasser T, et al. Update of the MDS research
criteria for prodromal Parkinson’s disease. Mov Disord 2019;34:
1464–1470.
16. Falony G, Joossens M, Vieira-Silva S, et al. Population-level analysis
of gut microbiome variation. Science 2016;352:560–564.
17. Zhernakova A, Kurilshikov A, Bonder MJ, et al. Population-based
metagenomics analysis reveals markers for gut microbiome composi-
tion and diversity. Science 2016;352:565–569.
18. Forslund K, Hildebrand F, Nielsen T, et al. Disentangling type 2 dia-
betes and metformin treatment signatures in the human gut micro-
biota. Nature 2015;528:262–266.
19. Valles-Colomer M, Falony G, Darzi Y, et al. The neuroactive potential
of the human gut microbiota in quality of life and depression. Nat
Microbiol 2019;4:623–632.
20. Booth FW, Roberts CK, Thyfault JP, et al. Role of inactivity in chronic
diseases: evolutionary insight and pathophysiological mechanisms.
Physiol Rev 2017;97:1351–1402.
21. Langsetmo L, Johnson A, Demmer RT, et al. The association
between objectively measured physical activity and the gut micro-
biome among older community dwelling men. J Nutr Heal Aging
2019;23:538–546.
22. Codella R, Luzi L, Terruzzi I. Exercise has the guts: how physical activ-
ity may positively modulate gut microbiota in chronic and immune-
based diseases. Dig Liver Dis 2018;50:331–341.
23. Longstreth GF, Thompson WG, Chey WD, et al. Functional bowel
disorders. Gastroenterology 2006;130:1480–1491.
24. Pilotto A, Heinzel S, Suenkel U, et al. Application of the movement
disorder society prodromal Parkinson’s disease research criteria in 2
independent prospective cohorts. Mov Disord 2017;32:1025–1034.
25. Goetz CG, Tilley BC, Shaftman SR, et al. Movement Disorder Soci-
ety-sponsored revision of the unified Parkinson’s disease rating scale
(MDS-UPDRS): scale presentation and clinimetric testing results. Mov
Disord 2008;23:2129–2170.
26. Somervuo P, Koskinen P, Mei P, et al. BARCOSEL: a tool for
selecting an optimal barcode set for high-throughput sequencing.
BMC Bioinformatics 2018;19:257.
27. Martin M. Cutadapt removes adapter sequences from high-through-
put sequencing reads. EMBnetjournal 2011;17:10–12.
28. Schloss PD, Westcott SL, Ryabin T, et al. Introducing mothur: open-
source, platform-independent, community-supported software for
describing and comparing microbial communities. Appl Environ
Microbiol 2009;75:7537–7541.
29. Kozich JJ, Westcott SL, Baxter NT, et al. Development of a dual-
index sequencing strategy and curation pipeline for analyzing
amplicon sequence data on the miseq illumina sequencing platform.
Appl Environ Microbiol 2013;79:5112–5120.
30. McMurdie PJ, Holmes S. Phyloseq: an R package for reproducible
interactive analysis and graphics of microbiome census data. PLoS
One 2013;8:e61217.
31. Le Chatelier E et al. Richness of human gut microbiome correlates
with metabolic markers. Nature 2013;500:541–546.
32. Claesson MJ, Cusack S, O’Sullivan O, et al. Composition, variability,
and temporal stability of the intestinal microbiota of the elderly. Proc
Natl Acad Sci U S A 2011;108:4586–4591.
33. Barichella M, Severgnini M, Cilia R, et al. Unraveling gut microbiota
in Parkinson’s disease and atypical parkinsonism. Mov Disord 2019;
34:396–405.
34. Qian Y, Yang X, Xu S, et al. Alteration of the fecal microbiota in Chi-
nese patients with Parkinson’s disease. Brain Behav Immun 2018;70:
194–202.
35. Keshavarzian A, Green SJ, Engen PA, et al. Colonic bacterial compo-
sition in Parkinson’s disease. Mov Disord 2015;30:1351–1360.
36. Odamaki T, Kato K, Sugahara H, et al. Age-related changes in gut
microbiota composition from newborn to centenarian: a cross-sec-
tional study. BMC Microbiol 2016;16:90.
37. Mancabelli L, Milani C, Lugli GA, et al. Unveiling the gut microbiota
composition and functionality associated with constipation through
metagenomic analyses. Sci Rep 2017;7:9879.
38. Vandeputte D, Falony G, Vieira-Silva S, et al. Stool consistency is
strongly associated with gut microbiota richness and composition,
enterotypes and bacterial growth rates. Gut 2016;65:57–62.
39. Hughes KC, Gao X, Molsberry S, et al. Physical activity and prodro-
mal features of Parkinson disease. Neurology 2019;93:e2157–e2169.
40. Estaki M, Pither J, Baumeister P, et al. Cardiorespiratory fitness as a
predictor of intestinal microbial diversity and distinct metagenomic
functions. Microbiome 2016;4:42.
41. Jackson MA, Jeffery IB, Beaumont M, et al. Signatures of early frailty
in the gut microbiota. Genome Med 2016;8:8.
42. Dalile B, Van Oudenhove L, Vervliet B, Verbeke K. The role of short-
chain fatty acids in microbiota–gut–brain communication. Nat Rev
Gastroenterol Hepatol 2019;16:461–478.
43. Unger MM, Spiegel J, Dillmann KU, et al. Short chain fatty acids and
gut microbiota differ between patients with Parkinson’s disease and
age-matched controls. Parkinsonism Relat Disord 2016;32:66–72.
44. Zhu L, Liu W, Alkhouri R, et al. Structural changes in the gut micro-
biome of constipated patients. Physiol Genomics 2014;46:679–686.
45. Morita E, Yokoyama H, Imai D, et al. Aerobic exercise training with
brisk walking increases intestinal bacteroides in healthy elderly
women. Nutrients 2019;11:868.
46. Ticinesi A, Lauretani F, Tana C, et al. Exercise and immune system as
modulators of intestinal microbiome: implications for the gut-muscle
axis hypothesis. Exerc Immunol Rev 2019;25:84–95.
47. Borghammer P, Van Den Berge N. Brain-first versus gut-first
Parkinson’s disease: a hypothesis. J Parkinsons Dis 2019;9:S281–
S295.
48. Venegas DP, De la Fuente MK, Landskron G, et al. Short chain fatty
acids (SCFAs)-mediated gut epithelial and immune regulation and its
relevance for inflammatory bowel diseases. Front Immunol 2019;
10:277.
49. Golubeva AV, Joyce SA, Moloney G, et al. Microbiota-related
changes in bile acid & tryptophan metabolism are associated with
gastrointestinal dysfunction in a mouse model of autism.
EBioMedicine 2017;24:166–178.
50. Ilett EE, Jørgensen M, Noguera-Julian M, et al. Gut microbiome
comparability of fresh-frozen versus stabilized-frozen samples from
hospitalized patients using 16S rRNA gene and shotgun meta-
genomic sequencing. Sci Rep 2019;9:13351.
August 2020 331
Heinzel et al: Prodromal Markers in PD
